The complete, honest guide to this once-monthly chew — how each ingredient works, who it is right for, who should use caution, and the critical questions your vet may not have time to answer at a routine visit.
Simparica Trio is a once-monthly chewable tablet that protects dogs against heartworm disease, six species of ticks, fleas, two types of roundworms, and two types of hookworms — all in a single dose. Manufactured by Zoetis and approved by the FDA on February 27, 2020, it was the first combination isoxazoline product for dogs in the United States. As of Q4 2024, it has been used to protect more than 15 million dogs. But with that reach comes responsibility: pet owners deserve the complete picture on how each ingredient works, what the real risks are, and which dogs should approach this medication with extra veterinary care. Here is what vets wish every dog owner knew before the first dose.
-
1
What exactly is Simparica Trio and what does it protect against? It is a once-monthly prescription chewable tablet combining three active ingredients to prevent heartworm disease, kill fleas and six tick species, and treat roundworms and hookworms.Simparica Trio (sarolaner + moxidectin + pyrantel pamoate) is manufactured by Zoetis and requires a veterinary prescription. One chew replaces what previously required two or three separate products. It is indicated for dogs and puppies aged 8 weeks and older weighing at least 2.8 pounds. The FDA approved the original four indications in February 2020 and added a fifth — treatment and control of the Asian longhorned tick (Haemaphysalis longicornis) — in a label expansion confirmed in November 2024, with studies showing 99.6% or greater efficacy against that species.
-
2
How does each of the three active ingredients work? Sarolaner paralyzes and kills fleas and ticks by blocking GABA and glutamate receptors. Moxidectin prevents heartworm larvae from developing into adults. Pyrantel pamoate paralyzes and expels roundworms and hookworms from the gut.The three mechanisms are complementary and non-overlapping. Sarolaner (an isoxazoline) works systemically: when a flea or tick bites a treated dog, the drug enters the parasite, over-excites its nervous system, and kills it. Moxidectin (a macrocyclic lactone) acts at chloride channels in heartworm larvae, causing paralysis and death of early-stage larvae that would otherwise mature into adult worms in the heart and lungs. Pyrantel pamoate (a tetrahydropyrimidine) functions primarily within the gastrointestinal tract, where it acts as a depolarizing neuromuscular-blocking agent that paralyzes and expels hookworms and roundworms. Each ingredient targets different parasites through different pathways, which is why the combination works so broadly.
-
3
Why must my dog be tested for heartworm before starting Simparica Trio? Because Simparica Trio prevents new heartworm infections but does not kill adult heartworms already present. Starting it in a heartworm-positive dog without veterinary supervision can cause serious reactions.Moxidectin targets only early-stage Dirofilaria immitis larvae (microfilariae and L3/L4 stages), not the adult worms that live in the heart and pulmonary arteries. According to the FDA-approved prescribing information, all dogs must be tested for existing heartworm infections before the product is administered. If a dog has a heavy microfilariae burden and is given Simparica Trio, a rapid die-off of microfilariae can trigger a systemic inflammatory response. Lab studies of heartworm-positive dogs given Simparica Trio at 1× and 3× the labeled dose did result in fever within 24 hours of the first dose, along with more frequent diarrhea. A veterinarian must determine whether a heartworm-positive dog is safe to treat with this medication and at what time in the heartworm treatment protocol to introduce it.
-
4
What are the most common side effects of Simparica Trio? Vomiting and diarrhea are the most frequently reported side effects in clinical trials. The FDA and Zoetis classify the overall adverse event rate as “very rare” — fewer than 1 report per 10,000 doses administered.In the field safety and effectiveness studies submitted to the FDA, 272 dogs received Simparica Trio for up to 11 monthly treatments. The adverse reactions reported in decreasing frequency were: vomiting, diarrhea, lethargy, anorexia, otitis externa (ear infection), pruritus (itching), polyuria (increased urination), hyperactivity, and polydipsia (increased thirst). Most were mild and transient. Zoetis publicly confirmed in 2022 that the global adverse event reporting rate — including all clinical signs such as vomiting, lethargy, diarrhea, and any neurological sign — is classified as “very rare” by international regulatory standards, meaning fewer than 1 report per 10,000 doses administered. Since its 2020 U.S. launch, over 15 million dogs have been dosed.
-
5
Can Simparica Trio cause seizures, and should I be worried about neurological side effects? Rare neurological reactions including tremors, ataxia, and seizures have been reported across the isoxazoline class. Seizures have occurred even in dogs without a prior history of neurological disease. The FDA requires this warning on the label.The sarolaner component of Simparica Trio belongs to the isoxazoline class. In September 2018, the FDA issued a public alert — and updated a pet-owner fact sheet in August 2021 — confirming that isoxazoline products across all brands (Bravecto, NexGard, Credelio, Simparica) have been associated with neurologic adverse reactions, including muscle tremors, ataxia, and seizures. These reactions have occurred in dogs with and without a prior history of neurological disorders. The official prescribing information for Simparica Trio carries this caution: use with care in dogs with a history of seizures or neurologic disorders. That said, the FDA continues to classify isoxazoline products as safe and effective for the majority of dogs. This is a risk that deserves an honest conversation with your veterinarian, particularly for dogs that have ever had a seizure or neurological episode.
-
6
Is Simparica Trio safe for Collies, Australian Shepherds, and other herding breeds with the MDR1 gene mutation? Generally yes at the labeled dose. Studies found Simparica Trio well-tolerated in MDR1-affected Collies at up to 3× the maximum labeled dose. At 5× the dose, ataxia was observed in one dog — important context but not a concern at normal dosing.Dogs with the MDR1 (ABCB1) gene mutation — common in Collies, Australian Shepherds, Shetland Sheepdogs, and related herding breeds — have a deficiency in P-glycoprotein, the blood-brain barrier pump that normally prevents drugs like moxidectin from accumulating in the central nervous system. The moxidectin dose in Simparica Trio (24 μg/kg) is calibrated for heartworm prevention, which is far below the doses historically associated with neurotoxicity in MDR1-affected dogs. FDA-required safety studies confirmed that MDR1-affected Collies tolerated Simparica Trio at 1×, 3×, and 5× the labeled dose; at 5× the dose, one dog showed mild, self-limiting ataxia and all dogs fully recovered within three days. At the normal prescription dose, Simparica Trio is considered safe even for MDR1-positive dogs, but owners of herding breeds should always disclose the breed and any genetic testing results to their veterinarian.
-
7
How fast does Simparica Trio start killing fleas and ticks? It begins killing fleas within 4 hours and achieves 100% flea kill at 8 hours. It begins killing deer ticks (black-legged ticks, the primary carrier of Lyme disease) within 8 hours after administration.In controlled laboratory studies submitted to the FDA, a single oral dose of Simparica Trio began killing fleas (Ctenocephalides felis) within 4 hours of administration and demonstrated 100% effectiveness at 8 hours. After weekly re-infestations in the same study, Simparica Trio reduced live flea counts by 97.8% or more within 12 hours of each infestation for the full 28-day dosing window. For tick control, the product was demonstrated to achieve 98.9% or greater effectiveness against existing infestations. Because sarolaner is systemic — meaning ticks and fleas must bite the dog to ingest it — it does not prevent a tick from attaching, but it kills it before it can transmit Borrelia burgdorferi (Lyme disease) or other tick-borne pathogens. The prescribing information notes that Simparica Trio is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
-
8
What happens if I miss a dose of Simparica Trio? Give the missed dose immediately when you remember, then resume the normal monthly schedule. If more than one month has passed since the last heartworm prevention dose, contact your vet — a follow-up heartworm test in approximately six months may be needed.The official prescribing guidance is clear: if a dose is missed, administer it as soon as you remember and resume monthly dosing. For heartworm prevention specifically, the product should be given year-round or at minimum within one month of first mosquito exposure each season and continued through at least one month after the last seasonal mosquito exposure. If switching from another heartworm preventive, Simparica Trio should be given within one month of the last dose of the prior medication. Missing more than one month of heartworm prevention is the primary concern, because heartworm larvae take approximately six months to mature to the adult stage where they appear on standard antigen tests. If a gap of several months has occurred, your veterinarian may recommend re-testing for heartworm at approximately six months after the gap to confirm no infection was established.
-
9
Can Simparica Trio be given with other medications, and are there known drug interactions? In clinical field studies, Simparica Trio was safely used alongside vaccines, antibiotics, and steroids. However, specific caution applies in MDR1-affected dogs receiving other P-glycoprotein-substrate drugs simultaneously.The prescribing information states there are no known contraindications for Simparica Trio. In large field safety studies, it was administered concurrently with a wide range of common veterinary products without evidence of adverse interactions. The critical exception involves dogs with confirmed or suspected MDR1 mutations: several drugs that are P-glycoprotein substrates — including cyclosporine (Atopica), certain antifungals (ketoconazole, itraconazole), and some cardiac medications — can compete with moxidectin for CNS efflux, potentially increasing moxidectin brain concentrations. Additionally, pyrantel pamoate should not be combined with levamisole, morantel, or piperazine, which can produce additive adverse effects. Always provide your veterinarian with a complete list of all current medications, supplements, and herbal products before starting Simparica Trio. Benzodiazepines warrant close monitoring when used concurrently with moxidectin.
-
10
Is Simparica Trio safe for puppies, pregnant dogs, and senior dogs? Safe for puppies aged 8 weeks and older, weighing 2.8 lbs or more. Safety in breeding, pregnant, or lactating dogs has NOT been established. Senior dogs generally tolerate it well, but an up-to-date heartworm test and vet review are essential before starting.The product is labeled for puppies as young as 8 weeks of age weighing at least 2.8 pounds (1.3 kg), making it one of the earliest-start parasite prevention options available. The FDA-approved label explicitly states that the safe use of Simparica Trio has not been evaluated in breeding males, pregnant dogs, or lactating (nursing) dogs. Veterinarians typically weigh the risks of parasite infection against the unknowns of drug exposure for pregnant or nursing dogs and may recommend alternative products for those situations. For senior dogs, there is no upper age limit, but older dogs with a history of seizures, renal disease, or hepatic disease warrant closer monitoring, given the liver and biliary system’s role as the primary route of sarolaner and moxidectin elimination. Annual heartworm testing remains recommended by the American Heartworm Society even for dogs on continuous prevention.
Sources: FDA CVM NADA 141-521 approval Feb 27 2020 (sarolaner, moxidectin, pyrantel; 8 weeks/2.8 lbs; fleas 4hr/8hr; 100% heartworm prevention); DailyMed NLM prescribing information (sarolaner 1.2 mg/kg; moxidectin 24 µg/kg; pyrantel 5 mg/kg; MDR1 5× ataxia, full recovery day 3; heartworm-positive fever within 24 hr; biliary elimination); dvm360 Jan 14 2025 (Asian longhorned tick label expansion, FDA Nov 2024, ≥99.6% efficacy); Zoetis Statement July 2022 (<1/10,000 global adverse rate; very rare classification; 10M+ dogs); Kynetec PetTrack Q4 2024 (15M+ dogs protected); FDA CVM Isoxazoline Fact Sheet Aug 2021 (neurologic reactions: tremors, ataxia, seizures; dogs with/without history); PMC12020015 MDR1 Credelio Quattro vs Simparica Trio comparison (moxidectin 48µg/kg max Simparica; blood-brain barrier P-gp mechanism); VCA Hospitals (drug interactions: cyclosporine, antifungals, benzodiazepines, pyrantel + piperazine contraindicated); American Heartworm Society (annual testing recommended)
Sources: FDA CVM NADA 141-521 (active ingredient mechanisms); DailyMed NLM full prescribing information (GABA/glutamate receptor inhibition; chloride channel mechanism; GI tract localization of pyrantel; first individual approvals: sarolaner 2016, moxidectin 1997, pyrantel 1977)
Sarolaner is a systemic drug, not a repellent. Fleas and ticks must bite the dog and ingest blood containing sarolaner to be affected. This means you may occasionally still find a dead tick on your dog. It does not mean the product is failing. Ticks are typically killed before they can transmit Lyme disease, which requires at least 36–48 hours of attachment in most studies.
Sources: FDA NADA 141-521 FOI Summary Feb 27 2020 (all efficacy figures, 20 lab studies + 3 field studies); DailyMed prescribing information; dvm360 Jan 14 2025 (H. longicornis label expansion ≥99.6%, 2 safety studies, FDA approval Nov 2024); Zoetis Petcare product page (6 tick species; Lyme prevention claim; Kynetec 2024 “only FDA-approved combo preventive to treat and control 6 kinds of ticks”)
Simparica Trio is administered once per month, orally, with or without food. It comes in six tablet sizes dosed by body weight. Always confirm current weight before selecting a tablet size — this is especially important for growing puppies. Each pack is color-coded.
| Box Color | Dog Weight | Sarolaner | Moxidectin | Pyrantel |
|---|---|---|---|---|
| 🟡 Gold | 2.8–5.5 lbs | 3 mg | 0.06 mg | 12.5 mg |
| 🟣 Purple | 5.6–11.0 lbs | 6 mg | 0.12 mg | 25 mg |
| 🟤 Brown | 11.1–22.0 lbs | 12 mg | 0.25 mg | 50 mg |
| 🟠 Orange | 22.1–44.0 lbs | 24 mg | 0.50 mg | 100 mg |
| 🔴 Red | 44.1–88.0 lbs | 48 mg | 1.0 mg | 200 mg |
| 🔵 Blue | 88.1–132.0 lbs | 72 mg | 1.5 mg | 300 mg |
Based on published consumer pricing, Simparica Trio typically costs $22–$30 per dose depending on the tablet size, pack size, and source of purchase. Purchasing a 12-count pack reduces the per-dose cost versus a 6-count or single dose. It is available by prescription only from your veterinarian, your vet’s online pharmacy, or external veterinary pharmacies with a valid prescription. Veterinarians sometimes sell individual doses for rapidly growing puppies who will need to move to the next tablet size within a few months.
Sources: DailyMed NLM prescribing information (minimum dosages 0.54 mg/lb sarolaner; 0.011 mg/lb moxidectin; 2.27 mg/lb pyrantel); 1800PetMeds / Heartland Vet Supply product listings (color-coded weight bands and tablet strengths); DailyPaws Sep 12 2025 ($22–$30 per dose; 12-pack savings)
Sources: Kynetec PetTrack US FTH National Data Jan 10 2025 / Q4 2024 review (15M+ dogs); FDA NADA 141-521 FOI (100% heartworm; flea 4hr/100% at 8hr); dvm360 Jan 14 2025 (Asian longhorned tick ≥99.6%); Zoetis Statement July 2022 (<1/10,000 very rare classification); DailyMed (8 weeks/2.8 lbs minimum; not evaluated pregnant/lactating/breeding)
This is one of the most important conversations to have with your veterinarian before starting Simparica Trio. The sarolaner component belongs to the isoxazoline class, which the FDA has formally linked to neurological adverse reactions including tremors, ataxia, and seizures in dogs with and without a prior seizure history. The prescribing information states: “Use with caution in dogs with a history of seizures or neurologic disorders.”
That does not mean it is absolutely contraindicated. Veterinarians routinely prescribe it to dogs with controlled epilepsy after a risk-benefit discussion. Factors your vet will consider include: how long ago the seizure occurred, whether your dog is currently on anti-epileptic medications, whether the cause of the seizure was ever diagnosed, and how well-controlled the condition currently is.
Alternatives to consider asking your vet about: Heartgard Plus (ivermectin + pyrantel) for heartworm/intestinal worms, with a separate topical or non-isoxazoline product for fleas and ticks. Spinosad (Comfortis, Trifexis) is a different insecticide class but also carries its own neurological warnings. A thorough veterinary review of your dog’s full history is the right starting point.
Both. Simparica Trio is labeled for treatment and control of existing tick infestations and for ongoing prevention of new ones. Sarolaner is a systemic drug that circulates in your dog’s bloodstream; when a tick bites and feeds, it ingests sarolaner and dies. Studies supporting FDA approval demonstrated ≥98.9% effectiveness against existing tick infestations at the time of dosing.
An important clarification: because it requires a bite to work, Simparica Trio does not repel ticks or prevent them from initially attaching. You may occasionally find a dead tick on your dog even while the medication is active. This is normal and expected. The critical question for disease transmission is not whether a tick attached, but whether it fed long enough to transmit pathogens. For Lyme disease, Borrelia burgdorferi transmission typically requires 36–48 hours of tick attachment. Simparica Trio kills ticks well before that window closes.
Still check your dog for ticks regularly after outdoor activity, especially in high-risk areas during peak tick season. Remove any dead ticks you find. Even dead ticks can occasionally cause localized skin reactions at the attachment site.
Year-round administration is the standard recommendation from both Zoetis and the American Heartworm Society, and here is why it matters even in cold climates.
Heartworm: Heartworm disease has been diagnosed in all 50 states. Even in northern states, unseasonably warm winters, travel to warmer climates, and indoor mosquito populations mean the risk is never truly zero year-round. The American Heartworm Society recommends continuous, year-round prevention without seasonal gaps.
Fleas and ticks: Ticks in particular are active at temperatures as low as 35°F. The black-legged tick (deer tick) is notoriously active in late fall and early winter. A single mild day in January can mean active tick exposure in wooded or leaf-littered areas.
Intestinal parasites: Roundworm and hookworm eggs persist in soil year-round and can be ingested during routine outdoor activities regardless of season.
If you choose seasonal dosing, the prescribing information specifies administering Simparica Trio within one month before first mosquito exposure and continuing through at least one month after the last seasonal mosquito exposure. Consult your vet for the appropriate seasonal window in your specific region.
This is a practical question the prescribing information addresses: if a dog vomits or spits out the dose, administer a replacement dose. Do not assume partial absorption is sufficient.
Vomiting is the most commonly reported side effect in clinical trials. It is usually a one-time event and not a sign that the medication was intolerable — many dogs vomit once and have no issues with subsequent monthly doses. Giving Simparica Trio with food (or as part of mealtime) can reduce the likelihood of vomiting, although the label states it can be given with or without food. In clinical studies, dogs consumed the chew by free choice or with food 91.9% of the time, suggesting palatability is generally high.
If your dog consistently vomits after each dose, discuss this pattern with your veterinarian. There may be an underlying gastrointestinal sensitivity to sarolaner or pyrantel, and a different product formulation might be more appropriate.
Yes, sarolaner (the isoxazoline component in Simparica Trio) is used off-label by veterinarians for the treatment of sarcoptic mange (caused by Sarcoptes scabiei) and demodectic mange (caused by Demodex canis). Off-label use is common in veterinary medicine when a drug has a mechanism of action that addresses a condition even if that use is not specifically listed on the approved product label.
Several peer-reviewed studies and clinical reports have documented sarolaner’s efficacy against demodectic and sarcoptic mange in dogs. However, because this is off-label use, the dosing schedule, duration of treatment, and monitoring requirements may differ from the standard monthly heartworm prevention schedule. Your veterinarian will determine whether Simparica Trio or standalone Simparica (sarolaner only) is the more appropriate option for mange treatment, depending on your dog’s overall parasite needs and health status.
Always follow your veterinarian’s specific directions for off-label use — the dosing and schedule for mange treatment may be significantly different from the label instructions.
All three are combination isoxazoline products offering broad-spectrum parasiticide coverage in a single monthly chew. Here is an honest comparison of the key differentiators:
- Tick coverage: Simparica Trio covers 6 tick species (including the Asian longhorned tick following the Nov 2024 label expansion). NexGard Plus covers 5 tick species. Credelio Quattro covers 5 tick species. This is currently a meaningful distinction for dogs in regions where H. longicornis has spread.
- Tapeworm coverage: Credelio Quattro contains praziquantel, directly treating Dipylidium caninum and Taenia tapeworms. Simparica Trio and NexGard Plus do not contain praziquantel — Simparica Trio only prevents flea tapeworm indirectly by killing fleas. If tapeworms are a concern in your dog, Credelio Quattro may be a more direct option.
- MDR1 safety data: A 2025 PMC peer-reviewed study found Credelio Quattro (lotilaner + lower moxidectin dose at 40 μg/kg max) was well-tolerated at 5× the recommended dose in MDR1-affected Collies with no neurological signs, while Simparica Trio (moxidectin up to 48 μg/kg max) showed mild, self-limiting ataxia in one dog at 5× the labeled dose. At the standard prescription dose, both are considered safe for MDR1-positive dogs.
- Age minimum: Simparica Trio and Credelio Quattro are approved from 8 weeks. NexGard Plus is approved from 8 weeks for some indications. Check current labeling for the specific product.
Your veterinarian is the best person to weigh these differences against your dog’s specific parasite risk profile, health history, and geographic location.
Mild reactions (single episode of vomiting, mild diarrhea, brief lethargy): Monitor closely, ensure your dog is hydrated, and call your vet to report the event during their next open hours. Most mild reactions are self-limiting within 24–48 hours.
Concerning reactions (repeated vomiting, bloody diarrhea, significant lethargy, loss of appetite lasting more than 24 hours, increased or decreased urination, itching, or ear problems): Contact your veterinarian on the same day. Do not administer the next monthly dose until your vet has reviewed what happened.
Emergency reactions (muscle tremors, wobbly gait or loss of coordination, facial swelling, hives, difficulty breathing, collapse, or seizures): This is a veterinary emergency. Go to your nearest emergency veterinary clinic immediately. Do not wait.
Because Simparica Trio is a long-acting oral medication with a 12-day half-life for sarolaner, there is no antidote — treatment is supportive. This is also why transparent reporting to your veterinarian and to Zoetis (888-963-8471) matters: adverse event data helps inform ongoing post-market safety surveillance. You can also report directly to the FDA at 240-402-7002 or through the FDA’s online adverse event reporting portal.
Sources: FDA CVM Isoxazoline Fact Sheet Aug 2021 (emergency contact info; reporting 240-402-7002); DailyMed prescribing information (sarolaner 12-day terminal half-life; biliary elimination; no known contraindications); PMC12020015 (2025 Credelio Quattro vs Simparica Trio MDR1 study; moxidectin dose comparison); Zoetis adverse event reporting 888-963-8471; VCA Hospitals (off-label mange use; drug interactions); DailyPaws Sep 2025 (vomiting free choice 91.9%); American Heartworm Society guidelines (year-round prevention; all 50 states)
- History of seizures or any neurological disorder — Isoxazoline class (sarolaner) has been formally associated by the FDA with tremors, ataxia, and seizures, even in dogs without prior neurological history. Dogs with existing neurological conditions face a different risk calculus entirely.
- Confirmed or suspected MDR1/ABCB1 gene mutation — Particularly relevant for Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and related herding breeds. At the labeled dose, moxidectin is considered safe even in MDR1-affected dogs, but concurrent P-glycoprotein-substrate drugs elevate the risk significantly.
- Known or suspected heartworm infection — The product is not effective against adult heartworms. Starting it in a heartworm-positive dog without veterinary guidance and supervision can trigger a microfilaricide reaction (fever, diarrhea, potential inflammatory response).
- Pregnant, lactating, or breeding dogs — Safety in these populations has not been established. Zoetis explicitly states the product has not been evaluated in breeding males, pregnant females, or nursing mothers.
- Puppies under 8 weeks of age or under 2.8 lbs — The product is not approved below these thresholds. The liver and kidney systems that clear sarolaner and moxidectin are not fully mature in very young puppies.
- Dogs on concurrent medications that are P-glycoprotein substrates — Cyclosporine (Atopica), ketoconazole, itraconazole, and certain cardiac drugs can interact with the moxidectin component in MDR1-affected dogs. Always disclose all current medications.
Sources: DailyMed prescribing information (minimum age/weight; heartworm-positive caution; not evaluated pregnant/lactating/breeding); FDA CVM Isoxazoline Fact Sheet (neurological adverse events class warning); PMC12020015 (MDR1/P-gp mechanism; CNS accumulation in ABCB1 mutant dogs); VCA Hospitals (P-gp substrate drug list; benzodiazepine monitoring; pyrantel interaction contraindications)
Simparica Trio requires a veterinary prescription. Allow location access when prompted to find the nearest resources. All map results are pulled from Google Maps — always call ahead to confirm availability and pricing.
- Step 1: Schedule a veterinary visit and ask for a heartworm test. The FDA requires all dogs be tested for existing heartworm infection before starting any heartworm preventive, including Simparica Trio. Your vet will also review your dog’s full medical history for neurological conditions, current medications, breed-specific genetic risks, and weight to select the correct tablet size.
- Step 2: Disclose your dog’s complete medication and supplement history. Include all prescription drugs, over-the-counter medications, flea and tick products, vitamins, and herbal supplements. P-glycoprotein substrate drugs can interact with moxidectin in MDR1-affected breeds. This is a step that is frequently skipped and matters more than most owners realize.
- Step 3: Give the correct size chew — weigh your dog first, every time. Simparica Trio is dosed by body weight across six tablet sizes. Giving an undersized dose reduces parasite protection; giving an oversized dose increases the risk of adverse events. Weigh puppies before each monthly dose — growing dogs frequently need to move to the next tablet size within a few months of starting the product.
- Step 4: Mark your calendar and never let heartworm prevention lapse. Heartworm prevention is not forgiving of gaps. A gap of just one month can allow larvae picked up during that window to develop past the stage that moxidectin can eliminate. Set a recurring reminder on your phone. If you do miss a dose, give it immediately, resume monthly dosing, and contact your vet about whether a follow-up heartworm test is warranted.
- Step 5: Monitor your dog for 24–48 hours after the first dose. First-dose reactions, though rare, are most likely to occur at the initial administration. Watch for vomiting, diarrhea, lethargy, changes in appetite, increased thirst or urination, and especially any signs of neurological involvement (tremors, unsteady gait, unusual eye movements). Report anything concerning to your veterinarian promptly. After a smooth first dose, subsequent monthly doses rarely produce any reaction at all.
- Starting it without a heartworm test. This is not optional guidance — it is FDA-required. A dog already infected with adult heartworms can develop a serious reaction when Simparica Trio kills circulating microfilariae. The test costs $25–$45 at most clinics and takes 10 minutes. Do not skip it.
- Stopping it in winter and thinking the dog is “protected.” Sarolaner and moxidectin do not accumulate in tissue between doses. Once a monthly dose clears the body, protection ends. A dog that has been off Simparica Trio for two months during winter has had no parasite protection during those two months. If an infected mosquito bit during that window, a heartworm infection may have been established, which will not become detectable until about six months later.
- Assuming it covers all worms. Simparica Trio does not treat tapeworms directly (only prevents flea-transmitted Dipylidium caninum by killing fleas), does not treat whipworms, and does not treat Giardia. If your dog has a known or suspected intestinal parasite infection beyond roundworms and hookworms, ask your vet about additional treatment with fenbendazole or praziquantel as appropriate.
© BestiePaws.com — This guide is independently researched and written. We are not affiliated with, compensated by, or endorsed by Zoetis, any veterinary pharmaceutical company, pet pharmacy, or insurance provider. All clinical information, efficacy figures, and safety data are sourced from FDA-approved prescribing information, peer-reviewed literature, and official government agency publications as of March 2026. Veterinary drug information changes — always confirm current prescribing guidance with your licensed veterinarian before making any medication decisions. This content does not constitute veterinary advice. Simparica Trio is a prescription product and requires a valid veterinarian-client-patient relationship to dispense. Report adverse drug events: Zoetis 1-888-963-8471 • FDA CVM 1-240-402-7002 • FDA Online Reporting: fda.gov/animal-veterinary
Primary sources: FDA CVM NADA 141-521 FOI Summary Feb 27 2020 (full approval; efficacy studies; adverse reactions; mechanisms; age/weight restrictions; heartworm-positive safety; MDR1 Collie safety studies); DailyMed NLM current prescribing information (dosing regimens; 6 color-coded tablet sizes; drug interactions; storage; no known contraindications; sarolaner 12-day half-life; biliary elimination); dvm360 Jan 14 2025 (Asian longhorned tick H. longicornis label expansion; FDA Nov 2024 FOI 16065; ≥99.6% efficacy; 2 safety studies; caution in dogs with seizure history); FDA CVM Isoxazoline Fact Sheet Aug 2021 (neurologic AEs: tremors, ataxia, seizures; with/without history; class-wide warning; reporting contacts); PMC7738705 isoxazoline safety survey (sarolaner adverse events; FDA/EMA reporting data); PMC12020015 2025 MDR1 Credelio Quattro vs Simparica Trio (ABCB1/P-gp mechanism; moxidectin CNS accumulation; 5× ataxia self-limiting; full recovery day 3; moxidectin dose comparison 48 vs 40 µg/kg); Zoetis Statement July 2022 (<1/10,000 very rare; 10M+ dogs); Kynetec PetTrack Q4 2024 (15M+ dogs; most widely prescribed); Zoetis Petcare product page (6 tick species; Lyme prevention B. burgdorferi; flea tapeworm prevention; 91.9% voluntary acceptance); 1800PetMeds (color-coded tablet sizes and strengths); VCA Hospitals (drug interactions: cyclosporine/Atopica; ketoconazole; itraconazole; benzodiazepines; pyrantel + piperazine/levamisole contraindication); DailyPaws Sep 12 2025 ($22–$30/dose; 12-pack savings; missed dose heartworm follow-up 6 months); Vetster Nov 2025 (MDR1 herding breeds; ongoing safety research; isoxazoline consensus); American Heartworm Society (year-round prevention; annual testing; all 50 states; 6-month detection window)